Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 2012

View Archived Issues

New strategy shows promise to eradicate latent HIV-1

ROCK inhibitor and calcium channel blocker show synergy in phase I trial

New PI3Kalpha and mTOR inhibitors designed in Spain

New antibacterial products presented

Aileron Therapeutics reports new candidate cancer therapies

Prostaglandin E2 derivative shows therapeutic potential in preclinical and clinical studies

New PARP-1 inhibitors synthesized in China

MediVector receives U.S. DOD contract to develop broad-spectrum influenza drug

SK Biopharmaceuticals launches phase II trial of constipation therapeutic

Genmab submits protocol amendment for phase III ofatumumab trial

Pharmaxis provides update on Bronchitol MAA

Medivir to file application for phase I trials of bone disorder candidate

NICE issues recommendation for dabigatran

Wintherix presents new activators of Wnt signaling

Novel somatostatin sst5 receptor antagonists developed

Novel E-NPP 2 inhibitors disclosed

Alcon and Astellas Pharma report new bradykinin receptor agonists

Boehringer Ingelheim Pharma designs new FLAP and leukotriene synthesis inhibitors

Novel hedgehog pathway activators divulged by Fate Therapeutics

FDA grants orphan drug status to verteporfin therapy

Telormedix completes safety portion of TMX-101 study

Galderma completes phase III studies of candidate for facial erythema of rosacea

Health Canada approves diclofenac therapy

TH-302 receives E.U. orphan drug status

Sodium channel blocker enters proof-of-concept trial

FDA proposes adjustment to risk classification of certain tuberculosis tests

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...